1
Hirohiko Shibayama, 2 and Yoshiaki Tomiyama 1, 2 BACKGROUND: There is an increasing demand for daratumumab (DARA), an immunoglobulin (Ig)G1κ monoclonal antibody (MoAb) that recognizes CD38, to manage relapsed or refractory multiple myeloma (MM) patients. However, DARA leads to positive and panreactive agglutination reactions in indirect antiglobulin tests (IATs) in vitro (the DARA interference). In addition, effects of DARA on red blood cells (RBCs) in vivo remains elusive.
STUDY DESIGN AND METHODS:
To develop a new method to negate the DARA interference, the effects of various concentrations of dithiothreitol (DTT) on RBC CD38 and Kell antigenicity in combination with an automatic blood cell washing centrifuge were compared with the AABB standard procedure in parallel. Moreover, direct antiglobulin tests (DATs) for RBCs in DARAtreated MM patients were examined.
RESULTS:
A quantity of 0.01 mol/L DTT as well as the AABB procedure (equivalent to 0.15 mol/L DTT in our procedure) markedly reduced the reactivity of phycoerythrin-mouse anti-CD38 MoAb and DARA with RBCs. In sharp contrast to the AABB procedure, 0.01 mol/L DTT partially preserved K antigenicity and allowed the determination of phenotype of K antigen even in the presence of the DARA interference. In contrast, DAT for RBCs obtained from MM patients showed a weak positive or negative reaction. Immunoblotting further indicated that DARA induced loss of CD38 in vivo.
CONCLUSION: A simple and reliable method to negate the DARA interference with partially preserving Kell antigenicity is proposed (Osaka method). CD38 antigenicity is susceptible to 0.01 mol/L DTT treatment even in the presence of DARA. Our data also demonstrate distinct effects of DARA on IAT in vitro and DAT in vivo.
C
D38 is a 46-kDa Type II transmembrane glycoprotein which consists of a short 20-amino-acid N-terminal cytoplasmic tail and a long 256-amino-acid extracellular domain. 1,2 CD38 is highly expressed on all malignant cells in multiple myeloma (MM), a malignant disorder characterized by neoplastic monoclonal expansion of plasma cells in the marrow. Of note, relatively low levels of CD38 expression on normal lymphoid and myeloid cells and in some tissues of nonhematopoietic origin enable this molecule to be an excellent target in the treatment of MM. 2, 3 In fact, daratumumab (DARA;
Genmab/Janssen), a humanized immunoglobulin (Ig)G 1 κ monoclonal antibody (MoAb) to CD38, was approved for the treatment of relapsed and/or refractory MM patients in September 2017 in Japan as well as in November 2015 by the Food and Drug Administration in the United States based on its high activity and favorable toxicity profile against those MM patients. [4] [5] [6] Since 
Immunoblotting
Red blood cell membrane fractions were obtained by repeated freezing and thawing, followed by repeated washing with 0.2% NaCl solution until the supernatant appeared colorless. Pellets of RBC membranes were then lysed with Laemmli sample buffer (Bio-Rad) with 2-mercaptoethanol. Proteins were separated on a 5% to 20% gradient gel by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). CD38 was detected by a mouse monoclonal anti-CD38 antibody (AT1, Santa Cruz Biotech). After stripping, loading amount was assessed by a mouse monoclonal anti-β-actin antibody (AC-15, Sigma). A representative result of two independent experiments is shown.
RESULTS

Effects of various concentrations of DTT on CD38 antigenicity
We examined effects of various concentrations of DTT on RBC CD38 antigenicity. The AABB procedure was examined in parallel. Since the AABB procedure added 4 vol of 0.2 mol/L DTT into 1 vol of RBCs, final DTT concentration is supposed to be 0.16 mol/L in our method. By contrast, in the Osaka method 50-μL DTT solution was added to 3 μL of RBCs (obtained from 100 μL of 3% RBC suspension), indicating that dilution of DTT concentration was negligible. As shown in Fig. 1, 0 .01 mol/L DTT treatment as well as the AABB procedure (equivalent to 0.15 mol/L) markedly reduced the reactivity of anti-CD38 MoAb with RBCs. In contrast, 0.005 mol/L DTT treatment only modestly reduced the reactivity. We also examined the effects of the AABB 0.01 mol/L DTT procedure, in which final concentration of DTT is supposed to be 0.005 mol/L. As expected, the AABB 0.01 mol/L DTT procedure showed essentially the same data as those obtained by 0.005 mol/L DTT in the Osaka method (data not shown). Thus, the AABB 0.01 mol/L DTT procedure as well as 0.005 mol/L DTT in the Osaka method did not have enough potential to markedly reduce the reactivity of anti-CD38 MoAb. It is also noteworthy that compared with low concentrations, high concentrations of DTT significantly increased a nonspecific IgG binding to RBCs, which suggests some damage on the RBC membrane after the AABB procedure. In fact, compared with normal ellipsoid RBCs (nontreated RBCs), which show bimodal forward scatter distribution, the AABB procedure disrupted the bimodal distribution and induced a shift to higher forward scatter, suggesting an increased spherical shape. 13 In contrast, 0.01 mol/L DTT induced a modest change in the distribution (Fig. 1) . Next, we examined effects of DTT treatment on DARA binding by employing plasma samples obtained from DARA-treated MM patients. Compared to the data with anti-CD38 MoAb, essentially the same results were obtained in regard to DARA binding (Fig. 2) . Since a residual amount of DARA binding was still detected after 0.01 mol/L DTT treatment (as shown in Fig. 2B ), we then examined if the residual binding might induce a positive result in PEG-IAT. Untreated RBCs were used as a positive control (+1). We found that DTT treatment at 0.01 mol/L or higher concentrations showed negative PEG-IAT, while 0.005 mol/L DTT treatment showed a weakly positive reaction (w+; Fig. 2D ). The negative results for PEG-IAT were probably due to low mean fluorescent intensity (MFI) for DARA as well as anti-CD38 MoAb binding. From these data, we determined that 0.01 mol/L DTT is the lowest concentration to sufficiently negate DARA-induced positive blood compatibility test.
Effects of DTT treatment on RBC antigenicity
It has been demonstrated that DTT treatment at 0.2 mol/L disrupt a limited number of blood group antigens. 7, 12 Among these blood group antigens, K is of particular importance, as anti-K is the only clinically relevant antibody to a DTT-sensitive antigen that is commonly encountered in the United States. 7 In this regard we examined effects of 0.01 mol/L DTT as well as the AABB procedure (0.15 mol/L DTT) on Kell and Duffy antigenicity by flow cytometry as well as tube testing. Both 0.01 mol/L DTT treatment and the AABB procedure markedly reduced K antigenicity, while both treatments did not affect Fy b antigenicity. However, compared to the AABB procedure, we demonstrated that substantial amounts of K antigenicity were preserved by 0.01 mol/L DTT (Fig. 3) . We then examined K antigenicity by tube testing. As shown in Table 2 were not disrupted by the AABB procedure or the Osaka method.
DTT at 0.01 mol/L treatment abolishes DARA binding but preserves K antigenicity
We then examined whether 0.01 mol/L DTT treatment might allow the determination of the phenotype of K antigen even in DARA-treated patients, since DARA may make DAT-positive in MM patients as described in the next paragraph. To test this ability, we incubated K-or K+ RBCs with plasma DARA samples obtained from MM patients and then washed three times in the automatic blood cell washing centrifuge. As shown in Fig. 4 , even K-RBC shows a positive result with anti-K because of the DARA interference. After 0.01 mol/L DTT treatment, K antigen phenotype became clearly identified by anti-K without the DARA interference. These data indicate that even after DARA administration, 0.01 mol/L DTT treatment abolishes the DARA interference and makes it possible to determine Kell antigen phenotype in MM patients.
Effects of DARA administration on RBC CD38 expression in MM patients
We (Fig. 5) . Plasma DARA samples were further added to each patient's RBCs. However, the increase of DARA binding was only minimal on Day 7 (or Day 8). These data suggested that DARA might reduce CD38 expression on the surface of RBCs. To examine these possibilities, we performed immunoblotting using RBCs obtained from MM patients. Figure 6 shows that the amounts of CD38 were markedly reduced in RBC lysates on Day 1 as well as on Day 7. These data indicated that DARA depleted CD38 expression from RBCs in MM patients in vivo.
DISCUSSION
There is an increasing demand for DARA and other humanized anti-CD38 MoAbs to manage relapsed or refractory MM patients based on their high activity. In addition, the DARA interference may persist for up to 6 months after DARA is discontinued. 8 Thus, from a viewpoint of transfusion medicine, development of a simple and suitable procedure for daily clinical examination to resolve the DARA interference is needed. In this regard, here we proposed the Osaka method instead of the AABB procedure (0.2 mol/L DTT) as a simple and suitable method for daily clinical examination to negate the DARA interference with preserving the Kell antigenicity. The Osaka method consists of 0.01 mol/L DTT treatment and an automatic blood cell washing centrifuge. In fact, our data presented in this study were obtained on RBCs treated by the Osaka method except immunoblotting. The extracellular domain of human CD38 contains six disulfide bonds that are critical to protein structure, and the structure of CD38 has been shown to be highly sensitive to reducing agents such as DTT.
14,15 DTT at 0.01 mol/L treatment is routinely used as a sulfhydryl reagent to abolish IgM antibody activity. 12, 16 In this regard, we examined whether low concentrations of DTT might disrupt the tertiary structure of CD38 by disulfide bond cleavage and negate the antigenicity in the flow cytometer, which was high enough to be detected by tube testing. The preservation of the Kell antigen is, at least in part, due to its high expression levels (approx. 2500-3000 molecules on each RBC for heterozygote), compared to CD38. 17 Compared to the Osaka method, the AABB procedure showed complete destruction of K antigenicity and increased nonspecific IgG binding, probably because of stronger RBC damage. In addition, the Osaka method has some advantages from a technical viewpoint. In contrast to the AABB procedure, the Osaka method uses an . This is the whole procedure of the Osaka method presented in this study, which we are able to finish within 60 minutes. DARA and other humanized anti-CD38 MoAbs have classic Fc-dependent immune effector mechanisms, including antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Compared with other CD38 MoAbs, DARA possesses stronger ability to induce complement-dependent cytotoxicity against MM cells, and DARA binds a unique epitope that is located on two β-strand-containing Amino Acids 233 to 246 and 267 to 280 of CD38. 4 However, we demonstrated that effects of DTT treatment on anti-CD38 MoAb binding were essentially the same between DARA and a commercially available mouse anti-human CD38. These data indicated that epitopes recognized by DARA or mouse anti-human CD38 MoAb were both susceptible to 0.01 mol/L DTT treatment and suggested that the whole antigenicity of CD38 was markedly impaired by 0.01 mol/L DTT treatment. In contrast to our data, the antigenicity of CD38 expressed on HL60 was susceptible to 0.005 mol/L DTT treatment. 7 It is possible that * Indicated RBC antigens were examined by specific antisera by tube testing. CD38 ectopically expressed on HL60 might be more susceptible to DTT treatment. It is noteworthy that even in the presence of DARA binding, 0.01 mol/L DTT negated the DARA binding and enabled us to determine the Kell antigen phenotype as shown in Fig. 4 . Thus, the Osaka method enables us to determine the Kell antigen phenotype of MM patients at any time point after DARA administration. Berthelier and colleagues 15 CD38 ligands. However, this is not the case with DARA, because even in the presence of DARA its epitope on CD38 was susceptible to 0.01 mol/L DTT, as shown in Fig. 4 . We further examined CD38 expression on RBCs obtained from MM patients with DARA administration. Consistent with a previous study, 18 we confirmed that DARA administration did not induce detectable RBC hemolysis in our patients even in the presence of DARA in their plasma (data not shown). DARA binding on RBCs obtained from each patient was detected on Day 1 by DAT, while it was not detected on Day 7 or Day 8. Immunoblotting revealed that the amounts of CD38 were reduced even on Day 1 and became almost undetectable on Day 7. Thus, loss of CD38 expression was induced by DARA administration in vivo, which might be responsible for the undetectable hemolysis in MM patients. While the precise mechanism that regulates DARA-induced CD38 loss on RBC remains determined, several mechanisms have been suggested. 17 In a murine model, antibody engagement can induce loss of target antigen, which typically occurs through an Fcγ receptor pathway. 18 Alternatively, DARA-CD38 complexes on RBCs may be actively transferred to monocyte and granulocyte as shown in myeloma cells (trogocytosis). 19 Further studies are needed to elucidate the precise mechanism. There are some limitations in this study. First, we did not examine whether the Osaka method might detect clinical examples of anti-K and/or anti-k obtained from DARAtreated MM patients by negating the DARA interference.
Second, the AABB procedure (0.2 mol/L DTT) has both advantages (can serve as a quality control indicator that DTT treatment has worked) and disadvantages (prevents detection of Kell antibodies). Using the Osaka method would mean trading the "loss-of-Kell quality control indicator" for the ability to detect Kell antibodies. In summary, we proposed a simple and reliable method for daily clinical examination to negate the DARA interference with partially preserving Kell antigenicity (Osaka method). We took advantage of the susceptibility of CD38 to 0.01 mol/L DTT even in the presence of DARA. Our method would provide a simple way to deal with DARA-containing plasma samples in daily clinical examination for transfusion. 
